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Summary
The sixteenth gene to cause autosomal dominant non-
syndromic hearing loss (ADNSHL), DFNA16, maps to
chromosome 2q23-24.3 and is tightly linked to markers
in the D2S2380-D2S335 interval. DFNA16 is unique in
that it results in the only form of ADNSHL in which
the phenotype includes rapidly progressing and fluctu-
ating hearing loss that appears to respond to steroid
therapy. This observation suggests that it may be pos-
sible to stabilize hearing through medical intervention,
once the biophysiology of deafness due to DFNA16 is
clarified. Especially intriguing is the localization of sev-
eral voltage-gated sodium-channel genes to the DFNA16
interval. These cationic channels are excellent positional
and functional DFNA16 candidate genes.
Introduction
Autosomal dominant nonsyndromic hearing loss
(ADNSHL) is a heterogeneous disorder. Twenty-two loci
have been identified (Hereditary Hearing Loss Home-
page, Van Camp and Smith), and seven of the relevant
genes have been cloned (in the following list, “DFN”
denotes “deafness,” “A” denotes “autosomal domi-
nant,” and the numerals denote the loci in the order in
their discovery): DFNA1,HDIA1 (MIM 124900 [Lynch
et al. 1997]); DFNA3, GJB2 (MIM 601544 [Denoyelle
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et al. 1998]); DFNA5,DFNA5 (MIM 600994 [Van Laer
et al. 1998]); DFNA8/12, TECTA (MIM 600994 [Ver-
hoeven et al. 1998]); DFNA9, COCH (MIM 601369
[Robertson et al. 1998]); DFNA11, MYO7A (MIM
601317 [Liu et al. 1997]); and DFNA15, POU4F3
(MIM 602459 [Vahava et al. 1998]) (table 1). Although,
by definition, the phenotype in each case is limited to
hearing impairment, some aspects of the hearing loss
appear to be locus specific.
Both age at onset and audiometric configuration can
be used to subclassify ADNSHL (see tables A1 and B1
[in Appendices A and B]). With respect to age at onset,
DFNA3 (Chaib et al. 1994), DFNA8 (Kirschhofer et al.
1998), DFNA12 (Verhoeven et al. 1997), and DFNA13
(Brown et al. 1997) are prelingual—and presumably
congenital—types of hearing loss. The hearing loss in
DFNA3 and DFNA8 is moderate to severe is degree,
nonprogressive, and predominantly high frequency. The
DFNA12 loss also is moderate to severe and nonpro-
gressive; however, the mid frequencies are affected, re-
sulting in a “cookie-bite” type of audiogram in some
hearing-impaired persons (Govaerts et al. 1998). A
cookie-bite pattern also is seen in DFNA13 in childhood,
but, by adulthood, age-related progression of the hearing
loss flattens the audiometric curve.
DFNA1 (Leon et al. 1992), DFNA2 (Coucke et al.
1994), DFNA5 (Van Camp et al. 1995), DFNA6 (Les-
perance et al. 1995), DFNA7 (Fagerheim et al. 1996),
DFNA11 (Tamagawa et al. 1996), and DFNA14 (au-
thors’ unpublished data) are postlingual early-onset (i.e.,
age !∼20 years) hearing losses. Among ADNSHL loci,
DFNA1, DFNA6, and DFNA14 are unique in that the
low frequencies are preferentially involved, resulting in
an up-sloping audiometric curve; with regard to these
loci, the loss begins at age ∼10 years (Appendix B). Oc-
casionally, a “hill-type” pattern is seen in DFNA6 during
the 1st decade of life, reflecting involvement of the low
and high frequencies, with initial sparing of the mid
frequencies; however, as the mid frequencies become af-
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Table 1
ADNSHL Loci
Locus Location Gene
DFNA1 5q31 HDIA1
DFNA2 1p32
DFNA3 13q12 GJB2
DFNA4 DFNA19q13
DFNA5 7p15 DFNA5
DFNA6 4p16.3
DFNA7 1q21-q23
DFNA8 11q TECTA
DFNA9 14q12-q13 COCH
DFNA10 6q22-q23
DFNA11 11q12.3-q21 MYO7A
DFNA12 11q22-q24 TECTA
DFNA13 6p21.3
DFNA14 4p16
DFNA15 5q31 POU4F3
DFNA16 2q24
DFNA17 22q
DFNA18 3q22
DFNA19 10 pericentromeric
DFNA20 Reserved
DFNA21 Reserved
DFNA22 Reserved
fected, the audiogram flattens. DFNA2, DFNA5,
DFNA7, and DFNA11 also have down-sloping audio-
metric curves. In DFNA2 (Marres et al. 1997; Kunst et
al. 1998), DFNA5, and DFNA7, onset of hearing loss
begins at age 5–15 years, with thresholds dropping to
∼80 dB at frequencies 11,000 Hz. The rate of progres-
sion varies and is most rapid with DFNA7. With all of
these loci, the final outcome is a gently sloping to flat
audiometric curve, usually by the individual’s mid 40s.
The slope of the DFNA11 loss is more gradual in com-
parison with that of DFNA2, DFNA5, or DFNA7, al-
though the loss in this case also is apparent during the
1st decade of life and is progressive.
DFNA4 (Chen et al. 1995b), DFNA9 (Manolis et al.
1996), and DFNA10 (O’Neill et al. 1996) are postlin-
gual progressive late-onset (i.e., during or after the 3d
decade of life) hearing losses. The loss begins during the
3d decade in the case of DFNA9, the 4th decade in the
case of DFNA4, and the mid to late 5th decade in the
case of DFNA10. Although bilateral amplification is re-
quired, DFNA9 hearing loss is the harbinger of a pre-
cipitous decline in word recognition, which correlates
with a sharp decrease in communication ability and
causes hearing aids to be of limited benefit.
Notably absent from this classification is fluctuating
hearing loss. This type of loss generally is associatedwith
autoimmune inner-ear disease (Tomiyama et al. 1995;
Katsarkas 1996), Me´nie`re disease (Filipo and Barbara
1997), and the dilated vestibular aqueduct (DVA) syn-
drome (Abe et al. 1997). However, it also can occur in
persons with ADNSHL. In this report, we describe the
localization of the first gene associated with fluctuating,
progressive ADNSHL: DFNA16.
Subjects and Methods
Clinical Description
This family was ascertained through the Department
of Otolaryngology, Okayama University Medical
School. The pattern of inheritance is consistent with
transmission of an autosomal dominant deafness-caus-
ing gene (fig. 1). Each affected person underwent pure-
tone audiometry (PTA) and a complete physical exam-
ination, to exclude syndromic forms of hearing impair-
ment. Additional tests performed to evaluate the hearing
loss of affected persons included temporal-bone com-
puted tomography and a western blot assay for anti–68-
kD inner-ear protein antibodies. Several affected persons
required in-patient treatment for sudden sensorineural
hearing loss (SNHL). Because of the unique features of
the hearing loss in this family, two cases will be described
in detail.
Case 1 (IV-6).—An 11-year-old competitive swimmer
was referred for an otolaryngological evaluation in early
1994 after a routine school health screen revealed prob-
able elevated hearing thresholds. His general health was
excellent, and his past medical history was unremark-
able. As an infant, he had shown no evidence of devel-
opmental or mental delay, no noticeable hearing loss,
and no delay in speech development. He had never ex-
perienced tinnitus or vertigo. Results of otoscopy were
normal, as was the remainder of his physical examina-
tion, with the exception of the presence of nasal allergies.
PTA revealed a bilateral sloping SNHL predominantly
affecting the higher frequencies (fig. 2a). No recruitment
was observed either by self-recording audiometry (Jerger
type I) or the short-increment sensitivity index (SISI) test
(0% at 0.5, 1, 2, and 4 kHz). Acoustic brain-stem re-
sponses were observed at 70 dB in the left ear and at
80 dB in the right ear. Results of temporal-bone com-
puted tomography were normal (fig. 3).
In April 1994, this individual first complained of left-
ear tinnitus. Audiometry confirmed a decrease in hearing
thresholds, and treatment with hydrocortisone, intra-
venous ATP, and vitamin B12 was initiated, resulting in
a temporally related recovery of hearing thresholds, to
pretreatment levels. A similar episode, also affecting the
left ear, occurred 3 mo later, and again, the administra-
tion of oral steroids (prednisolone) was temporally as-
sociated with an improvement in hearing thresholds (fig.
2b). Acute fluctuations in hearing with or without tin-
nitus became common (diagnoses were made on Decem-
ber 7, 1994 [left ear], April 2, 1996 [left ear], May 7,
1996 [right ear], August 13, 1996 [right ear], October
11, 1996 [left ear], December 25, 1996 [right ear], May
Figure 1 DFNA16 pedigree showing haplotypes assigned to minimize the number of recombination events (blackened circles denote affected females, and blackened squares denote affected
males). The map and map distances are shown in the square at the upper right (National Center for Biotechnology Information, Entrez; Whitehead Institute for Biomedical Research/MIT Center for
Genome Research). Paternal crossovers in II-1, II-3, and II-5 are indicated by a horizontal line; ages at last audiogram are as follows: IV-2, 15 years; IV-3, 21 years; IV-7, 16 years; IV-9, 11 years.
Response to steroids was clinically documented in III-4, III-7, IV-1, IV-6, and IV-8; similar data were not available for III-4, III-6, IV-4, and IV-5; generations I and II were profoundly deaf with no
recent fluctuations in hearing. IV-2 and IV-9 have critical recombinants that could affect the linked interval significantly; if IV-9 remains unaffected, the critical interval would be distal to marker
D2S124 and would not include D2S2380. II-5 represents a double recombination event (confirmed several times).
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Figure 2 Audiogram of IV-6 at initial presentation (a) and after the second (b) and last (c) episode of fluctuating hearing loss. The graph
summarizes chronological changes in hearing levels over a 27-mo period (circles and triangles represent right- and left-ear hearing levels,
respectively, at 2,000 Hz pure-tone stimulus, and horizontal bars at the bottom (d) indicate periods of steroid therapy.
8, 1997 [right ear], and August 15, 1997 [both ears])
(fig. 2d). Most of these episodes occurred during swim-
ming season, suggesting a possible relationship between
physical stress and hearing loss; however, themost recent
episode, in February 1998, followed a flulike infection.
Tinnitus was severe, and the hearing loss was bilateral
(fig. 2c). Again, a temporal response to corticosteroids
(hydrocortisone) was seen.
Case 2 (IV-8).—The younger sister of the boy described
in case 1 was referred for an otolaryngological evalua-
tion after she failed a preschool hearing screen at age 6
years. Her history was unremarkable for developmental
or medical problems, and there were no complaints of
either hearing loss or delays in language development.
Audiometry revealed a sloping, high-frequency SNHL;
SISI was 0% in the right ear and 5%–10% in the left
ear (fig. 4a).
On February 15, 1995, she experienced her first ep-
isode of acute hearing loss and promptly was put on a
regimen of therapy with betamethasone. By March 1,
1995, her hearing had recovered. A second episode of
hearing loss occurred in June 1996; recovery again was
temporally associated with the use of steroids. This cycle
repeated itself in August 1996, September 1996,October
1996, March 1997, May 1997, July 1997, and March
1998. The last episode followed the same flulike illness
that had affected her brother (fig. 4).
In an expanded investigation into the extended family,
all hearing-impaired persons stated that they had had
normal or nearly normal hearing until age 9–10 years.
Two persons did report some vertigo, but this had not
been associated with episodes of acute hearing loss. All
hearing-impaired females who had been pregnant re-
ported acute hearing loss and tinnitus immediately after
parturition. One hearing-impaired woman (III-4) who
suspected a relationship between physical stress and
hearing loss tried to avoid extremely rigorous activities
by her children (IV-4 and IV-5). Their hearing loss was
not as severe as that of their cousins (IV-6 and IV-8),
and they reported few episodes of fluctuation (fig. 5).
Genotyping
Genomic DNA was extracted from peripheral-blood
samples obtained from consenting family members, by
established procedures (Grimberg et al. 1989). After
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Figure 3 Computed tomography of temporal bone of IV-6 in
axial (a) and sagittal (b) planes, showing no evidence of a dilated
vestibular aqueduct.
linkage to known deafness-causing loci was excluded
(Hereditary Hearing Loss Homepage, Van Camp and
Smith), a genomewide screen was performed with 386
markers spaced an average of 10 cM apart (MapPairs
human screening set, version 8.0). PCR reactions were
performed as described elsewhere (Brown et al. 1997).
After PCR amplification, samples were electrophoresed
on a 6% denaturing polyacrylamide gel. Bands were
stained by SYBERGREEN (10 ml of 1:10,000) at room
temperature for 30 min and were visualized by Fluorl-
mager SI (Molecular Dynamics). Alleles were scored
manually by two investigators; when there were dis-
crepant or ambiguous results, the scoring was repeated.
Linkage Analysis
Two-point and multipoint linkage analysis was per-
formed by FASTLINK (Cottingham et al. 1993). Lia-
bility classes were assigned, with 50% penetrance for
subjects of age 10 years and with 90% penetrance for
subjects of age 110 years. The disease-allele frequency
was set at .0001, with the recombination fractions (v)
in males and females being considered to be equal. First,
two-point LOD-score analysis was performed first be-
tween the disease allele and each marker; then four-point
LOD-score analysis was performed with markers on
chromosome 2q.
Results
Linkage to the known deafness-causing loci (both
dominant and recessive) was excluded. Two-point ge-
nomewide linkage analysis was performed, and only two
loci, one on chromosome 2 and the other on chromo-
some 18, showed possible linkage (LOD score 12.0).
Additional markers were examined in both of these ar-
eas. A multipoint LOD score of 4.08 ( ) was ob-v  0
tained with D2S2345, over the D2S2380-D2S124-
D2S2345-D2S335 interval (fig. 6).
Discussion
DFNA16 is the 16th ADNSHL-causing gene to be
mapped and is characteristically unique when compared
with all previously characterized deafness-causing loci.
Persons in the pedigree that we studied have fluctuating
and, at times, rapidly progressive SNHL. These features
of DFNA16 hearing loss suggest that an understanding
of the relevant biophysiology may reveal ways to prevent
the fluctuation, thereby preserving, at some level, resid-
ual hearing.
Fluctuating SNHL is rare, accounting for !5% of all
SNHL of unknown etiology. In children, it is usually
diagnosed in association with either congenital cyto-
megalovirus (CMV) infection (Fowler et al. 1997) or
bony abnormalities of the inner ear, the latter most com-
monly being a DVA (Abe et al. 1997). The prevalence
of SNHL in persons with asymptomatic congenital CMV
is !10%, and, of this fraction, 20%–30% experience
fluctuating high-frequency hearing loss. In the pedigree
that we studied, there is no evidence consistent with
either this diagnosis or any other type of acquired hear-
ing loss.
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Figure 4 Audiogram of IV-8 at initial presentation (a) and after second (b) and last (c) episode of fluctuating hearing loss. The graph
summarizes chronological changes in hearing levels over a 30-mo period (circles and triangles represent right- and left-ear hearing levels,
respectively, at 2,000 Hz pure-tone stimulus, and horizontal bars at the bottom indicate periods of steroid therapy (d).
Figure 5 Audiograms of IV-4 at age 16 years and IV-5 at age
13 years. (Compare these results with those for IV-6 at age 13 years
[fig. 2c] and IV-8 at age 10 years [fig. 4c].)
DVA is defined as an enlargement of the endolym-
phatic duct and sac and is diagnosed by computed-tom-
ographic examination of the temporal bones (Abe et al.
1997). In as many as 80% of persons with DVA, fluc-
tuation in hearing occurs. This abnormality also is a
feature of branchiootorenal syndrome (Chen et al.
1995a), Pendred syndrome (Reardon et al. 1997), and
DFNB4 (Li et al. 1998). In this pedigree, there was no
evidence of syndromic hearing loss, and, although there
was marked fluctuation in hearing, normal temporal-
bone anatomy was documented in the two persons (cases
1 and 2) who underwent thin-cut computed tomo-
graphy.
In adults, fluctuating hearing loss is most commonly
seen in Me´nie`re syndrome (Filipo and Barbara 1997)
and autoimmune inner-ear disease (Tomiyama et al.
1995; Katsarkas 1996). The former is characterized by
both fluctuating SNHL that is often unilateral and pre-
dominantly in the low frequencies and vertigo that can
last for minutes to hours, and it is accompanied by nau-
sea and vomiting, as well as by constant or intermittent
tinnitus, which typically increases in intensity, either be-
fore or during the vertiginous attacks. Several families
have been described in which a Me´nie`re-syndrome gene
appears to be segregating (Morrison 1995); however, in
this pedigree the phenotype is inconsistent with this di-
agnosis. It is conceivable that other mutations of the
deafness-causing gene in this family could result in clas-
sic Me´nie`re syndrome. Phenotypic variability associated
with deafness-causing genes is well documented, and an
allelic variant of the gene COCH is known to produce
Me´nie`re-like symptoms (authors’ unpublished data).
Autoimmune inner-ear disease is characterized by bi-
lateral progressive asymmetric hearing loss (Veldman
1997). Approximately 65% of affected persons are mid-
dle-age women (Hughes et al. 1988), 25%–50% of
whom describe fluctuation in hearing and the presence
of vertigo, which initially may suggest the diagnosis of
Me´nie`re syndrome. The autoimmune reactionmay occur
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Figure 6 Multipoint-LOD-score results over interval defined in
figure 1.
either as part of the symptom complex of multisystemic,
non–organ-specific disease that occurs with rheumatoid
arthritis, Wegener granulomatosis, polyarteritis nodosa,
and systemic lupus erythematosis or as an organ-specific
process, which has been referred to as “primary auto-
immune inner-ear disease.” The diagnosis is facilitated
by the detection of an anti–68-kD antibody by western
blot. In a study of 279 persons with rapidly progressive
SNHL, 32% were positive for this antibody, and, of
those in whom the hearing loss was progressing during
the time of testing, 89% had a positive western blot
(Gottschlich et al. 1995). In this pedigree, although the
SNHL seemed to improve with corticosteroid adminis-
tration, the possibility of autoimmune inner-ear disease
appears unlikely, for several reasons: two individuals
tested by western blot while hearing loss was progressing
were negative for the anti–68-kD antibody; the family
history is negative for other autoimmune diseases; and
the age at onset is unusually early.
Corticosteroid therapy is the only treatment that has
proved effective in the treatment of sudden SNHL (Wil-
son et al. 1980; Moskowitz et al. 1984). Recommended
daily prednisone doses in adults are in the 60–80-mg
range, with a gradual decrease during the course of sev-
eral weeks. A response to therapy is more likely in per-
sons with hearing loss in the 40–80-dB range, and, if
the symptoms recur after the dosage has been decreased,
then resumption of prednisone, at a dosage of 40 mg/d
for 1 mo, and an autoimmune work-up are recom-
mended (Harris and Ruckenstein 1996). Although the
mechanism of action of prednisone is not known, it is
an anti-inflammatory drug that suppresses the immune
response. It also has a mineralocorticoid effect on fluid
and electrolyte balance, which is interesting in view of
the genes that have been mapped to the DFNA16
interval.
The DFNA16 interval is defined conservatively by
D2S2380 (centromeric) and D2S335 (telomeric) (see the
legend to fig. 1) on 2q23-q24.3, a chromosomal region
that includes three voltage-gated sodium chan-
nels—SCN1A, SCN2A1, and SCN3A (Malo et al. 1991;
GeneMap ’99). Cationic channels play an important role
in hearing, and mutations in three voltage-gated potas-
sium-channel genes—KVLQT1 (Neyroud et al. 1997),
KCNE (Tyson et al. 1997), and KCNQ4 (Kubisch et al.
1999)—are known to cause hearing loss (KVLQT1 and
KCNE1 result in Jervell and Lange-Nielsen syndrome,
and KCNQ4 results in DFNA2). Few data have been
reported on sodium channels; however, intracochlear ap-
plication of tetradotoxin, a sodium-channel blocker,
does affect cochlear response to electric stimulation (San-
tos-Sacchi 1993), and sodium channels appear to be im-
portant for inner-ear fluid regulation (Mizuta et al.
1995).
The demonstration that SCN1A, SCN2A1, and
SCN3A are cochlear expressed makes them excellent po-
sitional and functional candidate genes for DFNA16. If
one of these voltage-gated sodium channels is impli-
cated—because the phenotype includes fluctuating and,
at times, rapidly progressive SNHL—perhaps micro-
manipulation of the inner-ear environment by round-
window catheters can stabilize hearing. The clinical pos-
sibilities implicit in the unique features of the DFNA16
phenotype make this localization noteworthy.
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Appendix A
ADNSHL Loci Classified on the Basis of Age at Onset
of Hearing Loss
In the following list, the congenital losses are stable;
all others are progressive.
Congenital:
DFNA3
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DFNA8/12
DFNA13
Early onset (age !20 years):
DFNA1
DFNA2
DFNA5
DFNA6
DFNA7
DFNA11
DFNA14
DFNA16
Late onset (age 20 years):
DFNA4
DFNA9
DFNA10
Appendix B
ADNSHL Loci Classified on the Basis of Audiometric
Profile
In the following list, DFNA1 is quickly progressive,
with severe to profound SNHL at age !30 years;
DFNA6, and DFNA 14 are slowly progressive, with
some hearing present throughout life; DFNA6, DFNA7,
DFNA8/12, and DFNA12 have more than one audio-
metric profile; and DFNA16 entails fluctuating hearing
loss.
Low frequency (up sloping):
DFNA1
DFNA6
DFNA14
Mid frequency (cookie bite):
DFNA12
DFNA13
High frequency (up sloping):
DFNA2
DFNA3
DFNA5
DFNA7
DFNA9
DFNA10
DFNA16
High/low frequency (hill shape):
DFNA6
All frequencies (flat):
DFNA4
DFNA7
DFNA11
DFNA8/12
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